Tag Archive for: BioTech and Pharma

Jesse McCool, PhD, Joins Cytovance Biologics as Vice President, Microbial Services

Former Director, Process Development at Lonza Biologics

Life Science Partner recruited Jesse McCool, an innovative and energetic R&D leader, to become Vice President, Microbial Services for Cytovance Biologics.

Founded in 2003, Cytovance is one of the premier biological contract companies of therapeutic proteins and antibodies from mammalian cell culture to microbial fermentation.

“Jesse brings considerable new microbial cell development savvy and strong leadership skills to help build out this new product line for Cytovance,” said Tom Callaway, MD, President of Life Science Partner.  “His enthusiasm is infectious.”

In his new role at Cytovance, McCool will report to the Chief Scientific Officer and will direct microbial biologics process discovery and development activities.  He will manage partnerships with client organizations to assure strategic and tactical efforts are executed in accordance with global biologics regulatory submissions.

During his tenure at Lonza, McCool was successful in expanding offerings in Microbial Process R&D Services and improving Lonza’s market presence as Director, Microbial Process Development.

McCool earned his Bachelor of Science Degree and PhD in Microbiology from the University of Massachusetts at Amherst.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Tina Webb Joins Allergan as Director, Business Compliance, Pharmaceuticals

Life Science Partner recruits former Associate Director, US Pharmaceuticals Compliance and Ethics for Bristol-Myers Squibb

Allergan, Inc. is a technology-driven, multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices in the areas of eye care, neurosciences, medical dermatology and urologics. The company is best known for its Botox franchise.

Tina Webb, an experienced pharmaceutical compliance executive, has joined Allergan as the Director of Business Compliance, Pharmaceuticals. 

In this role, she will be responsible for providing advice and leading efforts regarding Allergan’s compliance policies and procedures for the pharmaceutical business within the United States.  She will work with the sales force to build communication strategies and messages that are effective but consistent with the product’s approved uses – and create solutions that enhance physician customer relations with the CIA guidelines.

In her previous role at Bristol-Myers Squibb, Webb was responsible for developing, overseeing and maintaining the Company’s US Compliance and Ethics program.  She successfully brought automation and systemization of the compliance program that allowed the sales and marketing organization to function more effectively while in compliance.

“Tina has an analytical and legal approach to compliance combined with a sales-oriented personality,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “Her broad experience in creating and implementing compliance programs for US Sales and Marketing organizations will be a great asset for the Allergan Compliance team.”

Webb earned her degree from Rutgers University in New Brunswick, NJ.

About Life Science Partner

Life Science Partner’s high-quality executive, research and professional placement services target the very specific needs of life sciences and healthcare organizations. We identify and recruit the brightest talent in the biotechnology, pharmaceutical, medical device, academic and healthcare services fields.  Our combined scientific backgrounds and senior management experience give us the scientific literacy and business knowledge to help us better understand challenges, refine requirements and work more effectively with our life science clients.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Cathy Srebalus-Barnes, PhD Joins Hospira as Senior Director, Bioanalytical Sciences

Former Director, Bioproduct Analytical Development at

Eli Lilly and Company

Life Science Partner announces the recruitment of Cathy Srebalus-Barnes, PhD, an experienced bioanalytical executive, to become Senior Director, Bioanalytical Sciences, Global Biologics R&D for Hospira, Inc.

Hospira is a global specialty pharmaceutical and medication delivery company that develops, manufactures and markets products that help improve the safety, effectiveness and costs of patient care.

In her new role at Hospira, Inc., Srebalus-Barnes will lead a global scientific team responsible for bioanalytical method development and bioanalytical characterization activities supporting Hospira’s growing biosimilars pipeline.

Srebalus-Barnes has spent much of her career at Eli Lilly and Company, where she was most recently responsible for leading three teams of scientists that included Analytical Development, Trace Analysis and Bioassay groups.  She oversaw the complete downstream process for Phase II – ready for III preparation for therapeutic biotechnology products in clinical and commercial development.  Previously, Srebalus-Barnes served as Director, Bioprocess Virology and Purification Development, where she was responsible for two groups managing the purification process development and viral safety procedures for all biotechnology products in development.

Barnes earned a Bachelor of Science Degree in Chemistry from West Virginia University and her Doctorate from Indiana University in Analytical Chemistry.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Nancy Grygiel joins Allergan as Senior Director, Corporate Compliance, International

Life Science Partner recruits former Director of Global Compliance Program at Mylan Pharmaceuticals

Life Science Partner announces the recruitment of Nancy Grygiel, an experienced global compliance executive, to Allergan, Inc. to become Senior Director, Corporate Compliance, International for the company.

Allergan is a technology-driven, multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices in the areas of eye care, neurosciences, medical dermatology and urologics.

In Grygiel’s previous role at Mylan Pharmaceuticals, a Pennsylvania-based company developing generic and specialty pharmaceuticals, she was responsible for overseeing the global compliance program operations across North American, Asia Pacific, Europe and Middle East, and India and China.

Prior to joining Mylan, Grygiel practiced as an International Business Transactions and Immigration Specialist at the Law Offices of Paul S. Haar in Washington, DC.

“Nancy is an articulate and passionate compliance officer with a personality and communication skills that allow her to succeed in four languages,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “Her vast international experience and global compliance background will serve Allergan well in its mission to commercialize important new therapies that make a real difference.”

Grygiel earned her degree in Legal Studies from the Universidad De Buenos, Aires and then received her Master of Law Degree from Georgetown Law Center.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Mark Suto joins the Southern Research Institute as Vice President of Drug Discovery

Life Science Partner recruits former Vice President, Chemical and Pharmaceutical Sciences at Icagen, Inc.

Life Science Partner announces the recruitment of Mark Suto, PhD, an experienced scientist and drug discovery executive, to the Southern Research Institute in Birmingham, Alabama.

Southern Research Institute.  With a focus on the discovery and advancement of new, small-molecule therapeutics from the design stage to the clinic, Southern Research’s Drug Discovery Research Division has accomplished innovative research in the areas of cancer, infectious disease and neuroscience.

Suto was previously Vice President at Icagen, a biopharmaceutical company focused on the novel small molecule drugs that target ion channels in diverse therapeutic areas. He was responsible for leading discovery and development chemistry activities, including medicinal, bioanalytical and computational chemistry for the company.  Previously, he served as Executive Vice President and Chief Scientific Officer at Neurion Pharmaceuticals.

“Suto is a passionate and articulate individual, with an impressive background in drug discovery,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “He will bring infectious enthusiasm along with 28 years of large pharmaceutical and biotechnology experience to the team at Southern Research.”

Suto earned his Bachelor of Science Degree and PhD in Medicinal Chemistry from the State University of New York at Buffalo.

/0 Comments/by

Thomas Nikolai to Join Hospira as Senior Director, External Biologics Collaborations and Partnerships

Life Science Partner recruits former Director, Biologics, Parenteral Products at Abbott Laboratories

Life Science Partner announces the recruitment of Thomas Nikolai, MS, MBA, to become Senior Director, External Biologics Collaborations and Partnerships for Hospira’s biosimilars division.

Hospira is a global specialty pharmaceutical and medication delivery company that develops, manufactures and markets products that help improve the safety, effectiveness and costs of patient care.

Nikolai leaves Abbott with over 20 years of leadership experience in biologics process development, technical operations and manufacturing support.  In his most recent role, Nikolai served as Director, Biologics, Parenteral Products, where he was the Global CMC leader for commercial and late-stage biologic drug products including Humira, Abbott’s blockbuster arthritis drug.

“Nikolai is a passionate and results-driven professional with a progressive technical management career in the biopharmaceutical industry.” noted Tom Callaway, MD, Founder and President of Life Science Partner.  “He brings a wealth of knowledge and leadership to the biologics team at Hospira and will serve the company well as it provides biosimilar versions of the world’s most critical biological drugs.”

Nikolai received his Bachelor of Science Degree in Chemical Engineering and Bioengineering from the University of Wisconsin, Madison and his Masters of Science in Biochemical Engineering from the University of Minnesota, Twin Cities.  He earned a Masters in Business Administration from the University of Wisconsin, Parkside.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Peter Lacouture Joins Hospira as Medical Director, Pain Management

Life Science Partner Recruits Pain Clinical Specialist from Purdue Pharma and Co-Founder of Magidom Discovery

Life Science Partner announces the recruitment of Peter Lacouture, PhD, to become Medical Director of Pain Management for Hospira.

Hospira is a global specialty pharmaceutical and medication delivery company that develops, manufactures and markets products that help improve the safety, effectiveness and costs of patient care.  The company recently acquired Javelin Pharmaceuticals to take advantage of the synergies between Javelin’s main product candidate, DylojectTM ,a post-operative pain management drug and Hospira’s proprietary sedation agent PrecedexTM.

In 2001, Lacouture co-founded Magidom Discovery, a pharmaceutical services company focused on all aspects of research and development for pain management drug development.  This followed his long tenure at Purdue Pharma where he served as the Senior Director of Clinical Research.  In his new role at Hospira, Lacouture will have overall responsibility for the clinical development of the expanding portfolio of pain drugs under development, as well as leading the decision process regarding the potential clinical utility and regulatory strategy of pain management compounds.

“Lacouture has a strong background in clinical development of acute pain drugs – both as the leader of compounds in development in a major leader in the space, as well as with small companies as a consultant,” noted Tom Callaway, MD, President of Life Science Partner.  “His considerable network of key opinion leaders in the space will serve Hospira well as it continues to expand it considerable portfolio of pain managements drugs and systems.”

Lacouture earned a Bachelor of Arts degree in Chemistry from the College of Holy Cross, Worcester.  He received his Masters in Pharmacology/Toxicology and his PhD in Pharmacology/Physiology from the Massachusetts College of Pharmacy and Allied Health Sciences, Boston.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Neil Schauer, PhD joins Hospira as Senior Director, Biologics Process Development

Life Science Partner recruits former Director of DSP Research and Development at Millipore Corp

Life Science Partner announces the recruitment of Neil Schauer, PhD, a seasoned biopharmaceutical development leader and scientist, to become Senior Director, Biologics Development for Hospira’s biosimilars division.

Hospira is a global specialty pharmaceutical and medication delivery company that develops, manufactures and markets products that help improve the safety, effectiveness and costs of patient care.

In his most recent role at Millipore Corp, Schauer was responsible for scientific and managerial leadership of a large research and development organization with four functional areas focusing on DSP Research.  Prior to his tenure at Millipore Corp, Schauer served as the Director of Cambridge Manufacturing Sciences at Biogen Idec.  In his new role at Hospira, he will have overall responsibility for providing strategic and technical leadership to a large staff of pharmaceutical scientists responsible for the development of Drug Substance and Drug Product manufacturing for Hospira’s biosimilar products.

“Schauer is a versatile leader and scientist with a solid background in managing large teams in the identification and development of disruptive new technologies” noted Tom Callaway, MD, Founder and President of Life Science Partner.  “With his global knowledge and reach, he will serve Hospira well in its mission to become a global leader in providing biosimilar versions of the world’s most critical biological drugs.”

Schauer earned a Bachelor of Science in Biochemistry and Biology and his PhD in Anaerobic Microbiology from the Virginia Polytechnic Institute, Blacksburg.

/0 Comments/by

Bill Frey joins Georgia Pacific as Vice President, Business Development, Disruptive Technologies

Life Science Partner recruits former President and Chief Executive Officer of Qteros

Life Science Partner announces the recruitment of William  (Bill) Frey, PhD, most recently President and Chief Executive Officer for Qteros, to Georgia Pacific to lead a new business development initiative on disruptive technologies across the company. 

In this role, Frey will be responsible for key areas of investment, such as the use of biotechnology in processing of wood products, materials sciences to create new products, and process engineering to reduce water and energy utilization for a more sustainable business enterprise.

Frey is well qualified to develop this initiative at Georgia Pacific from his leadership at Qteros, a cellulosic ethanol technology company dedicated to accelerating the global commercialization of renewable biofuels.

Previously, Frey served as Global Business Director at DuPont Biofuels where he led global business activities and commercialization of Advanced Biofuels and New Cellulosic Process technologies for the company, resulting in the formation of DuPont Biofuels.   Frey has a significant track record for championing innovation during his 28 years at DuPont, including the creation of new biotechnology-based businesses.

“Frey brings his broad experience and successful insights in identifying and executing transformative opportunities in biofuels and sustainable chemicals and materials to the company,” noted Tom Callaway, President of Life Science Partner.  “His unique blend of developing strategic partners from both sides – large company to small and small company to large – will serve him well in his new role.”

Frey earned his Bachelor of Science Degree in Chemistry from King’s College in Wilkes-Barre, PA.  He received a PhD in Organic Chemical with an Enzymology and Biochemistry focus from Pennsylvania State University.  He completed his Postdoctoral Fellowship at Harvard Medical School.

/0 Comments/by

Dr. Scott Treiber joins Hospira as Vice President of Clinical Operations and Medical Affairs

Life Science Partner recruits former Executive Vice President at inVentiv Clinical Solutions

Life Science Partner announces the recruitment of Scott Treiber, PhD, an experienced clinical research leader, to Hospira to become Vice President of Clinical Operations and Medical Affairs.

Hospira is a $5 B global specialty pharmaceutical and medication delivery company based in Lake Forest, Illinois.

Previously Treiber served as Executive Vice President Clinical Development at inVentiv Clinical Solutions.  He had responsibility for all aspects of clinical monitoring and project management, including executive project oversight and client interaction for full service clinical trials managed by the company.   Earlier Treiber held senior-level positions at leading Contract Research Organizations, including PharmaNet, Quintiles, ICON and Premier Research.

“Treiber has a depth of experience in clinical development organizational management in a wide range of therapeutic categories including neuroscience, cardiovascular, general medicine and oncology,” noted Tom Callaway, MD, President of Life Science Partner.  “His global CRO background will serve the company well as it transforms its business to a more diversified pharmaceutical company including a portfolio of biosimilar drugs.”

Treiber earned his Bachelor of Science Degree in Biology from the University of Iowa and his PhD in Biology from the University of California Santa Cruz.  He completed his MBA from Ellis College, New York Institute of Technology.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by